Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Satoshi Akahane is active.

Publication


Featured researches published by Satoshi Akahane.


The Journal of Urology | 2002

Effects of Selective β2 and β3-Adrenoceptor Agonists on Detrusor Hyperreflexia in Conscious Cerebral Infarcted Rats

Kouichi Kaidoh; Yasuhiko Igawa; Hiroo Takeda; Yoshinobu Yamazaki; Satoshi Akahane; Hiroshi Miyata; Yukiyoshi Ajisawa; Osamu Nishizawa; Karl-Erik Andersson

ABSTRACTPurpose: We evaluated the effects of β-adrenoceptor agonists on detrusor hyperreflexia in cerebral infarcted rats.Materials and Methods: To produce cerebral infarction in Sprague-Dawley rats the left middle cerebral artery was occluded by introducing a monofilament nylon thread into the artery. In sham operated rats the same artery was exposed but not occluded. After these operations cystometric and cardiovascular experiments were performed with no anesthesia or restraint.Results: After the operation bladder capacity was significantly decreased and voiding pressure was significantly increased in cerebral infarcted but not in sham operated animals. The difference in cerebral infarcted and sham operated rats was significant for each parameter (p <0.01). Post-void residual urine volume was not affected in either group. In the cerebral infarction group intravenous administration of CL316243 ([R,R]-5–2-[[2-(3-chlorophenyl-2-hydroxyethyl]-amino]propyl] -1,3-benzodioxole-2,2-dicarboxylate) (Kissei Centra...


The Journal of Urology | 2010

CXCR3 Binding Chemokine and TNFSF14 Over Expression in Bladder Urothelium of Patients With Ulcerative Interstitial Cystitis

Teruyuki Ogawa; Toshiki Homma; Yasuhiko Igawa; Satoshi Seki; Tetsuya Imamura; Satoshi Akahane; Yukio Homma; Osamu Nishizawa

PURPOSE We investigated the genes responsible for ulcerative interstitial cystitis by DNA microarray analysis and quantitative real-time polymerase chain reaction. MATERIALS AND METHODS Bladder urothelial tissues were taken from a site apart from the ulcerative lesion in 9 patients with ulcerative interstitial cystitis and from a normal-looking area in 9 controls, including 7 with bladder carcinoma and 2 with benign prostatic hyperplasia. Total RNA was extracted from bladder samples and gene expression was compared between these 2 groups using Whole Human Genome DNA microarray 44K (Agilent Technologies, Santa Clara, California). Microarray data were analyzed by GeneSpring GX software and Ingenuity Pathway Analysis. Chosen genes were confirmed for altered transcription by quantitative real-time polymerase chain reaction. RESULTS We identified 564 probes that were significantly expressed in mRNA more than 4-fold vs those in controls using volcano plot analysis (p <0.001). Further network Ingenuity Pathway Analysis of these genes showed the top 3 functions, including 1) cell-to-cell signaling and interaction, and hematological system development and function, 2) inflammatory disease and 3) cellular development. Quantitative real-time polymerase chain reaction confirmed increased mRNA expression of several genes in the bladder samples of patients with ulcerative interstitial cystitis, including CXCR3 binding chemokines (CXCL9, 10 and 11) and TNFSF14 (LIGHT). CONCLUSIONS Our study using DNA microarray analysis followed by quantitative real-time polymerase chain reaction reveals over expression of genes related to immune and inflammatory responses, including T-helper type 1 related chemokines, and cytokines such as CXCR3 binding chemokines and TNFSF14. These genes may be potential interstitial cystitis biomarkers.


Endocrine | 2004

Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.

Yutaka Mori; Fumiki Oana; Akane Matsuzawa; Satoshi Akahane; Naoko Tajima

The effect of short-term bezafibrate (BF) administration over time on the expression of adiponectin mRNA in the tissues was examined in Otsuka Long Evans Tokushima Fatty (OLETF) rats. Eight-week-old rats were divided into the high-dose (100 mg/kg) BF group (n=15), the low-dose (10 mg/kg) BF group (n=15), or the control group (n=15) and followed up for 14 d. Triglyceride and free fatty acid levels significantly decreased in a dose-dependent manner in the high-dose BF group. The insulin levels increased with time, although they were significantly lower in the high-dose BF group on d 3 and 7 than the control group. Adiponectin levels significantly increased in the high-dose BF group. On d 14 of BF administration, the levels of VLDL and chylomicron were significantly lower in BF groups, and adiponectin mRNA expression in the white adipose tissue was significantly higher in the high-dose BF group. Findings from this study suggest that in type 2 diabetes with insulin resistance, hypertriglyceridemia is closely linked to adiponectin.


Bioorganic & Medicinal Chemistry | 2001

β3-Adrenoceptor agonists for the treatment of frequent urination and urinary incontinence: 2-[4-(2-{[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)phenoxy]-2-methylpropionic acid

Nobuyuki Tanaka; Tetsuro Tamai; Harunobu Mukaiyama; Akihito Hirabayashi; Hideyuki Rasukasasu Azumino Muranaka; Satoshi Akahane; Masuo Akahane

In a search for novel analogues of beta(3)-adrenoceptor (AR) agonists relaxing the bladder for treatment of urinary dysfunction, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acids (1a-e), into which a fibrate-like structure had been incorporated, were synthesised. Compound 1a was found to be a selective beta(3)-AR agonist in functional assays using the ferret detrusor (beta(3)-AR), rat uterus (beta(2)-AR), and rat atrium (beta(1)-AR); beta(3): EC(50)=7.8 nM, beta(2): IC(50)=7,300 nM, beta(1): EC(20)=23,000 nM. The introduction of a chlorine atom or methyl substituent at the ortho-position on the phenyl ring of 1a further improved beta(3)-AR selectivity. In an in vivo study, 1a lowered intrabladder pressure (ED(50)=31 microg/kg) in rats, without increasing heart rate, in keeping with the in vitro results. Consequently, it is proposed that 1a and its analogues (1b-e), possess beta(3)-AR agonistic activity in the absence of undesirable beta(1)- or beta(2)-AR mediated actions, and may be useful for clinical treatment and pharmacological studies.


Endocrine Research | 2010

KTO-7924, a Beta3-adrenergic Receptor Agonist, Reduces Hyperglycemia, and Protects Beta-cells in the Islets of Langerhans of db/db Mice

Fumiki Oana; Hiroo Takeda; Akane Matsuzawa; Satoshi Akahane; Morimichi Hayashi; Toru Tamura; Miyuki Uehara; Masayuki Isaji; Masuo Akahane

Introduction. The effect of beta3-adrenergic receptor agonists on beta cells in the islets of Langerhans is not yet clear. This study examined the beta3-adrenergic receptor agonist on beta cells in the islets of Langerhans. Methods. Obese diabetic C57BL/KsJ-db/db mice were treated with KTO-7924, a newly-developed beta3-adrenergic receptor agonist for 28-day. We analyzed plasma parameters, insulin resistance, and insulin-positive areas among beta-cells in the islets of Langerhans. Results and Conclusion. After a 28-day oral administration period, plasma levels of hemoglobin (Hb) A1c, glucose, triglyceride (TG), and free fatty acid (FFA) were all significantly reduced in KTO-7924 treatment groups compared with controls. Plasma adiponectin levels decreased with age in the control group, but were significantly higher in a treatment group throughout the study period. Furthermore, sequential administration of KTO-7924 led to an improvement in insulin resistance in the OGTT (Oral glucose tolerance test (OGTT)), and an increase in the percentage of insulin-positive areas among beta-cells in the islets of Langerhans compared with controls. This is the first study to show islet histology after treatment of a beta3-adrenergic receptor agonist, and reveals that KTO-7924 reduces hyperglycemia, and protects beta-cells in the islets of Langerhans of db/db mice.


Neurourology and Urodynamics | 2002

Effects of beta(3)-adrenoceptor stimulation on prostaglandin E-2-induced bladder hyperactivity and on the cardiovascular system in conscious rats

Hiroo Takeda; Yoshinobu Yamazaki; Yasuhiko Igawa; Kouichi Kaidoh; Satoshi Akahane; Hiroshi Miyata; Osamu Nishizawa; Masuo Akahane; Karl-Erik Andersson


Metabolism-clinical and Experimental | 2005

Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin

Fumiki Oana; Hiroo Takeda; Kohichi Hayakawa; Akane Matsuzawa; Satoshi Akahane; Masayuki Isaji; Masuo Akahane


The Journal of Urology | 2003

Functional Characterization of β-adrenoceptor Subtypes in the Canine and Rat Lower Urinary Tract

Hiroo Takeda; Akane Matsuzawa; Yasuhiko Igawa; Yoshinobu Yamazaki; Kouich Kaidoh; Satoshi Akahane; Masami Kojima; Hiroshi Miyata; Masuo Akahane; Osamu Nishizawa


Journal of Medicinal Chemistry | 2003

Relationship between Stereochemistry and the β3-Adrenoceptor Agonistic Activity of 4‘-Hydroxynorephedrine Derivative as an Agent for Treatment of Frequent Urination and Urinary Incontinence

Nobuyuki Tanaka; Tetsuro Tamai; Harunobu Mukaiyama; Akihito Hirabayashi; Hideyuki Rasukasasu Azumino Muranaka; Junichi Kobayashi; Satoshi Akahane; Masuo Akahane


European Journal of Pharmacology | 2005

Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a β3-adrenoceptor agonist

Fumiki Oana; Hiroo Takeda; Akane Matsuzawa; Satoshi Akahane; Masayuki Isaji; Masuo Akahane

Collaboration


Dive into the Satoshi Akahane's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiromu Harada

Kyoto Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Naoko Tajima

Jikei University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge